Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

The following is a summary of “Endoscopy and Anesthesia Outcomes Associated with Glucagon-Like Peptide-1 Receptor Agonist Use ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including neurocognitive and ...

Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney ...

Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...